Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its quarterly earnings results on Tuesday. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.09, Zacks reports. Swedish Orphan Biovitrum had a return on equity of 17.72% and a net margin of 4.74%.

Swedish Orphan Biovitrum Stock Performance

BIOVF opened at $45.72 on Tuesday. The business has a 50 day moving average price of $46.31 and a two-hundred day moving average price of $43.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. The company has a market capitalization of $16.27 billion, a price-to-earnings ratio of 21.67 and a beta of 0.47. Swedish Orphan Biovitrum has a 1-year low of $34.88 and a 1-year high of $49.03.

Analyst Ratings Changes

A number of brokerages recently weighed in on BIOVF. Pareto Securities cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Nordea Equity Research cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.